Canadian healthcare firm Concordia said Tuesday that it will buy British firm Amdipharm Mercury in a deal worth $1.9 billion. The London company has a portfolio of 190 drugs which are bought from major pharma firms when they are off-patent. They have customers worldwide. Concordia said that Amdipharm is a “powerful cash machine” with more than half a million dollars (pro-forma) of sales expected from the acquisition in 2015.
More market talk: